IOLCP Unveils ₹495 Crore Expansion Plan: 50% Ibuprofen Capacity Boost and CDMO Entry
IOL Chemicals and Pharmaceuticals (IOLCP) has initiated a multi-pronged ₹495 crore expansion strategy at its Barnala facility to solidify its global leadership in Ibuprofen and diversify into higher-margin segments. The plan includes a massive 50% capacity hike for its core Ibuprofen product alongside the launch of new CDMO and specialty chemical verticals.
Morepen Labs Completes Phase 1 Expansion; API & CDMO Capacity Hits 614 KL
Morepen Laboratories has successfully finished the first phase of its manufacturing capacity expansion program ahead of its internal deadline. The expansion increases the company's total installed reactor capacity for API and CDMO operations from 535 KL to 614 KL, supporting a strategic shift toward higher-scale commercial supplies.
Shilpa Medicare Commissions Integrated ADC Manufacturing Facility in Dharwad
Shilpa Biologicals Private Ltd, a subsidiary of Shilpa Medicare, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP manufacturing facility. Located in Dharwad, the plant enables end-to-end production of complex oncology biologics for global markets.